Patents Assigned to Fox Chase Cancer Center
  • Publication number: 20190211359
    Abstract: RNA virus vectors comprising a gene encoding the DNA-dependent activator of interferon-regulatory factors (DAI) protein, and optionally further comprising a gene encoding the receptor-interacting serine/threonine-protein kinase 3 (RIPK3) may be used therapeutically to induce cell death, as well as an inflammatory immune response, against tumors and virally-infected cells.
    Type: Application
    Filed: July 5, 2017
    Publication date: July 11, 2019
    Applicant: Institute For Cancer Research d/b/a The Research Institute Of Fox Chase Cancer Center
    Inventors: Siddharth Balachandran, Roshan Thapa
  • Patent number: 9611321
    Abstract: Methods for generating hybrid antibodies are provided.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: April 4, 2017
    Assignee: Fox Chase Cancer Center
    Inventors: Gregory P. Adams, Heidi H. Simmons, Matthew K. Robinson, Roland Dunbrack, Andreas Lehmann
  • Patent number: 9522078
    Abstract: An apparatus and method are provided for positioning a patient on a surgical platform. The apparatus includes an elongated flexible web and a plurality of extension straps for connecting the apparatus to the surgical platform. Each extension strap includes a connector configured for connecting the apparatus to the platform. Adjustment mechanisms allow the extension straps to be adjusted to vary the tension in the web. The medical professional selects the desired position and orientation of the patient on the surgical platform and manipulates the patient into the desired position and orientation. A retention device is connected to a surgical platform and placed over the patient at the appropriate portion of the patient. A second end of the retention device is connected to a second side of the surgical platform. The retention device is then adjusted to increase the tension in the retention device.
    Type: Grant
    Filed: July 21, 2008
    Date of Patent: December 20, 2016
    Assignee: FOX CHASE CANCER CENTER
    Inventor: Mark-Alan D. Pizzini
  • Patent number: 9451904
    Abstract: An apparatus is provided, which utilizes an adjustment platform for supporting a subject during the endoscopic examination. Additionally, a method for performing an endoscopic examination is also provided in which an endoscope is inserted into a subject and the endoscope is maintained at a generally fixed position while the position of the subject is adjusted to advance the endoscope into the subject. Further still, a method is provided for estimating the size of sample tissue using an endoscope and a reference element. Based on known parameters of the reference element, the size of the area being examined can be estimated.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: September 27, 2016
    Assignee: FOX CHASE CANCER CENTER
    Inventors: Harvey Hensley, Margie Clapper
  • Patent number: 9346814
    Abstract: The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: May 24, 2016
    Assignees: Universiteit Antwerp, Fox Chase Cancer Center
    Inventors: Koen Jansen, Ingrid De Meester, Leen Heirbaut, Jonathan D Cheng, Jurgen Joossens, Koen Augustyns, Pieter Van Der Veken
  • Patent number: 9296687
    Abstract: Compositions and methods for modulating HSP70 function, particularly for the targeted killing of cancer cells, are disclosed.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: March 29, 2016
    Assignees: Fox Chase Cancer Center, The Trustees of the University of Pennsylvania
    Inventors: Donna L. George, Julia I-Ju Leu, Maureen Murphy
  • Publication number: 20150353928
    Abstract: The invention relates to methods of inhibiting the growth or proliferation of a cell, the method comprising reducing the expression or activity of at least one gene in the cell selected from the group consisting of BLOC1S1, CDC2L1, CNOT1, CYR61, DDX54, EIF3I, FANCG, FBP1, IER2, KIF1A, LCK, NR2F1, PNRC1, POLR2A, POLR2B, POLR2C, PRPF6, PSMB4, PSMC5, PSMD1, PTK7, RPS2, SCNN1A, SF3A3, TAF2, TOB1, TSC22D4.
    Type: Application
    Filed: September 14, 2012
    Publication date: December 10, 2015
    Applicants: Georgetown University, Fox Chase Cancer Center
    Inventor: Louis M. WEINER
  • Patent number: 9181322
    Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?,TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: November 10, 2015
    Assignee: Fox Chase Cancer Center
    Inventor: Kerry S. Campbell
  • Patent number: 9150636
    Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?, TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: October 6, 2015
    Assignee: Fox Chase Cancer Center
    Inventor: Kerry S. Campbell
  • Patent number: 9101631
    Abstract: Compositions which act synergistically to inhibit the growth of cancer cells and methods of use thereof are disclosed.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: August 11, 2015
    Assignees: Georgetown University, Fox Chase Cancer Center
    Inventors: Vladimir Ratushny, Erica A. Golemis, Ilya G. Serebriiskii, Louis M. Weiner, Igor Astsaturov, Andrew Godwin
  • Publication number: 20150119263
    Abstract: Disclosed are devices that comprise a protein, such as an antibody, placed into electronic communication with a semiconductor material, such as a carbon nanotube. The devices are useful in assessing the presence or concentration of analytes contacted to the devices, including the presence of markers for prostate cancer and Lyme disease.
    Type: Application
    Filed: August 30, 2012
    Publication date: April 30, 2015
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, FOX CHASE CANCER CENTER
    Inventors: Alan T. Johnson, JR., Mitchell Lerner, Matthew K. Robinson, Tatiana Pazina, Dustin Brisson, Jennifer Dailey
  • Patent number: 8980258
    Abstract: Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: March 17, 2015
    Assignees: The Regents of the University of California, Fox Chase Cancer Center
    Inventors: Gregory P Adams, Eva M. Horak, Louis M. Weiner, James D. Marks
  • Publication number: 20140357650
    Abstract: The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.
    Type: Application
    Filed: January 17, 2013
    Publication date: December 4, 2014
    Applicant: Fox Chase Cancer Center
    Inventors: Koen Jansen, Ingrid De Meester, Leen Heirbaut, Jonathan D. Cheng, Jurgen Joossens, Koen Augustyns, Pieter Van Der Veken
  • Publication number: 20140275162
    Abstract: Treating Sonic Hedgehog-Associated Medulloblastoma comprises inhibiting the synthesis or biologic activity of leukotrienes that drive Nestin expression in cancerous or precancerous granule neuron precursors and that further drive growth and proliferation of medulloblastoma cells through Nestin-mediated aberrant Sonic Hedgehog signaling.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center
    Inventor: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center
  • Publication number: 20140272947
    Abstract: A high-throughput method for identifying a compound or biomolecule that modulates cell senescence involves simultaneously measuring in a cell population exposed to the test compound or biomolecule, the expression of a senescence marker and cell number, wherein each well contains a single test compound; and determining from said simultaneous measurements whether the test compound increases or decreases cell senescence. In various embodiments, the method is useful is identifying compounds that delay the aging process of normal healthy cells, or identifying a compound useful as a tumor suppressor or identifying a compound useful in the treatment of cancer.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 18, 2014
    Applicants: Fox Chase Cancer Center, The Wistar Institute of Anatomy and Biology
    Inventors: Rugang Zhang, Benjamin Guy Bitler, Jeffrey Peterson
  • Patent number: 8802432
    Abstract: Methods of promoting liver morphogenesis prior to the functioning of blood vessels by culturing liver cells with endothelial cells is provided. Also provided are cell cultures and method of promoting vasculogenesis of liver tissue by contacting liver cells with endothelial cells.
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: August 12, 2014
    Assignee: Fox Chase Cancer Center
    Inventors: Kenneth S. Zaret, Kunio Matsumoto, Hideyuki Yoshitomi
  • Publication number: 20140193764
    Abstract: The invention provides aromatherapy devices that may be used to break a capsule containing a desired aromatic liquid, and then control the release of the aroma as the volatile aromatic liquid evaporates. The devices may be used, for example, in aromatherapy, including to control nausea or to mask unpleasant scents.
    Type: Application
    Filed: March 13, 2014
    Publication date: July 10, 2014
    Applicant: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center
    Inventor: Mark-Alan Pizzini
  • Publication number: 20140186365
    Abstract: Antibodies that specifically bind to an epitope on the serum albumin, including human and/or mouse serum albumin are provided. Nucleic acids encoding such antibodies and cells capable of expressing such antibodies are also provided.
    Type: Application
    Filed: March 14, 2013
    Publication date: July 3, 2014
    Applicants: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center, Oncobiologics, Inc.
    Inventors: Matthew K. Robinson, John K. Cini, Jimson W. D'Souza
  • Publication number: 20140172454
    Abstract: A method and system for scheduling, tracking, recording, and monitoring of patients' usage of an infusion room, along with various tools to analyze the infusion room activity, to thereby improve usage of the infusion room, and improve patient satisfaction relating to their infusion room experience, is disclosed. The inventive methods and systems use real-time computer processors, software, and distributed sensors to monitor, record, analyze, and graphically display relevant infusion room chair status, patient status, and patient medical condition while in the infusion room. In preferred embodiments, the inventive methods and systems provide real-time input capability for medical personnel, and real-time automatic data output for use by or to prompt medical personnel. The inventive methods and systems are capable of recording activity of the infusion room to permit later analysis, modeling, and simulation to allow for improvements in infusion room efficiencies and patient satisfaction.
    Type: Application
    Filed: March 14, 2013
    Publication date: June 19, 2014
    Applicant: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center
    Inventor: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center
  • Publication number: 20140163087
    Abstract: Methods for treating tumors comprising cells expressing the vitamin D receptor are provided, and comprise inhibiting the expression or the biologic activity of the vitamin D receptor in the tumor cells, and/or inhibiting the expression or the biologic activity of a constituent of the vitamin D receptor signaling pathway in the tumor cells, and administering to the tumor cells an effective amount of gemcitabine.
    Type: Application
    Filed: December 26, 2013
    Publication date: June 12, 2014
    Applicant: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center
    Inventors: Timothy J. Yen, Vikram Bhattacharjee